To further study the downstream targets of PI3K/mTOR pathway, five breast cancer cell lines BT-474, MCF-7, MDA-361, MDA-436 and SK-BR-3 were treated with PI3K inhibitor Ly294002 and mTOR inhibitor rapamycin (Figure 1). This evidence concerns the gene PIK3CA and breast carcinoma.